Cowen 40th Annual Health Care Conference

Our 40th Annual Health Care Conference continues to thrive on collaboration and teamwork. Our intention is to always identify essential industry themes and innovations and provide our clients with a breadth and depth of expertise.
Phil Nadean, PH.D - " An example of when the Cowen Conference helped bring to light a new discovery was in 2015, when our breast cancer panel talked about a new antibody drug Conjuagte for breast cancer called IMMU-132. After these comments, Cowen really dug in, and we initiated coverage of the company. We made it a tip pick, and Cowen's Investment Banking group helped finance immunomedics. Today, IMMU-132 is in front of FDA, and we are hopeful for an approval later this year. Our Consultants still expect it to become standard of care in the treatment of triple negative breast cancer"
https://www.youtube.com/watch?v=8ysZvbgrMBM